AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Haemato AG

Regulatory News Service Nov 15, 2023

5404_rns_2023-11-15_e6a12801-a5f8-4951-8b36-d768904ab450.html

Regulatory News Service

Open in Viewer

Opens in native device viewer

News Details

Ad-hoc | 15 November 2023 19:42

Termination of the botulinum toxin project

HAEMATO AG / Key word(s): Strategic Company Decision

Termination of the botulinum toxin project

15-Nov-2023 / 19:42 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.


Berlin, 15. November 2023 – Due to new findings on changed market conditions, an updated validation of the profitability of the company’s own botulinum toxin project was carried out.  After reviewing various options, the Executive Board decided today to terminate the cooperation with the Korean manufacturer Huons BioPharma and to discontinue the project for a proprietary botulinum toxin. This decision has no impact on the company’s operating business .

About HAEMATO :

HAEMATO AG was founded in 1993 and is a pharmaceutical company with a focus on the trading of high-priced specialty pharmaceutical drugs (with a therapeutic emphasis on oncology, HIV, rheumatology and other chronic diseases) as well as the development and distribution of medical products and own brands, particularly in the area of “Lifestyle & Aesthetics”. HAEMATO AG is listed on the Basic Board (Open Market) of the Frankfurt Stock Exchange. Further information can be found at https://haemato.de .

Contact:

HAEMATO AG, Investor Relations

Telefon: +49 (0)30 897 30 86 70

[email protected]

End of Inside Information


15-Nov-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Archive at www.eqs-news.com


Language: English
Company: HAEMATO AG
Lilienthalstraße 5c
12529 Schönefeld
Germany
Phone: +49 (0)30 897 30 86 70
Fax: +49 (0)30 897 30 86 79
E-mail: [email protected]
Internet: www.haemato.ag
ISIN: DE000A289VV1
WKN: A289VV
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Stuttgart, Tradegate Exchange
EQS News ID: 1774581
End of Announcement EQS News Service

show this

Talk to a Data Expert

Have a question? We'll get back to you promptly.